EGFR-PI3K-AKT-mTOR signaling in head and neck squamous cell carcinomas

• Verfasst von: Freudlsperger, Christian [VerfasserIn]
• Verfasst von: Burnett, Jeffrey R [VerfasserIn]
• Verfasst von: Friedman, Jay A [VerfasserIn]
• Verfasst von: Kannabiran, Vishnu R [VerfasserIn]
• Verfasst von: Chen, Zhong [VerfasserIn]
• Verfasst von: Van Waes, Carter [VerfasserIn]
• Titel: EGFR-PI3K-AKT-mTOR signaling in head and neck squamous cell carcinomas
• Titelzusatz: attractive targets for molecular-oriented therapy
• Verf.angabe: Christian Freudlsperger, MD, DDS, Jeffrey R. Burnett, BS, Jay A. Friedman, PhD, Vishnu R. Kannabiran, BS, Zhong Chen, MD, PhD, and Carter Van Waes, MD, PhD
• Jahr: 2011
• Umfang: 12 S.
• Fussnoten: Autorenmanuskript, verfügbar in PMC 2012 Juli 18 ; Online veröffentlicht: 26 Nov 2010 ; Gesehen am 08.03.2023
• Titel Quelle: Enthalten in: Expert opinion on therapeutic targets
• Ort Quelle: Abingdon, Oxon : Routledge, Taylor & Francis, 1997
• Jahr Quelle: 2011
• Band/Heft Quelle: 15(2011), 1, Seite 63-74
• ISSN Quelle: 1744-7631
• DOI: doi:10.1517/14728222.2011.541440
• Datenträger: Online-Ressource
• Sprache: eng
• Sach-SW: Akt
• Sach-SW: EGFR
• Sach-SW: head and neck squamous cell carcinoma
• Sach-SW: mTOR
• Sach-SW: PI3K
• Sach-SW: targeted therapy
• K10plus-PPN: 1838570403

Abstract

Importance of the field: Recent advances in the understanding of the oncogenesis of head and neck squamous cell carcinomas (HNSCC) have revealed multiple dysregulated signaling pathways. One frequently altered axis is the EGFR-PI3K-Akt-mTOR pathway. This pathway plays a central role in numerous cellular processes including metabolism, cell growth, apoptosis, survival and differentiation, which ultimately contributes to HNSCC progression. Areas covered in this review: Books, journals, databases and websites have been searched to provide a current review on the subject. What the reader will gain: This article reviews the current understanding of EGFR-PI3K-Akt-mTOR signaling in HNSCC, including the impact of both genetic and epigenetic alterations. This review further highlights the potential of targeting this signaling cascade as a promising therapeutic approach in the treatment of HNSCC. Take home message: Genetic alterations of several nodes within this pathway, including both genetic and epigenetic changes, leading to either oncogene activation or inactivation of tumor suppressors have frequently been implicated in HNSCC. Consequently, drugs that target the central nodes of this pathway have become attractive for molecular oriented cancer therapies. Numerous preclinical and clinical studies are being performed in HNSCC; however, more studies are still needed to better understand the biology of this pathway.